Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2022

View Archived Issues

Identification of sites of metabolic liability for KRM-II-81 and evaluation of a deuterated analogue

Variant in the CTR1 gene causes novel disorder of copper metabolism

MK-6158: sGC stimulator clinical candidate for pulmonary arterial hypertension

Novel nonhallucinogenic DMT analogues as drug candidates for mental health and addiction disorders

Phosphatidylserine is crucial for synaptic pruning in adult-born neurons

New antibacterials identified at Roche

Yale University divulges new oligosaccharyltransferase complex inhibitors

HDAC inhibitors disovered at Chong Kun Dang Pharmaceutical

Dompe Farmaceutici describes new peptides with angiogenic activity

Bayer patents P2X purinoceptor 4 antagonists

Novel USP30 inhibitors as potential anti-Parkinson candidates

Novartis details discovery, preclinical data of novel antimalarial compound INE-963

Sosei Heptares' GLP-1/2 agonist HTL-0030023 shows promising results for treating NAFLD and NASH

Missense variants in DDX39B linked to novel syndrome of global neurodevelopmental delay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...